EC awards Allergan license to market bimatoprost/timolol solution

June 8, 2006

The European Commission (EC) granted Allergan a license to market bimatoprost/timolol ophthalmic solution (Ganfort) in the European Union. The once-daily combination product is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension whose disease is insufficiently responsive to topical beta-blockers or prostaglandin analogues.